T
Tesis Labs
A unique integrated medical platform that is revolutionizing targeted genetic sequencing
About Tesis Labs
Tesis Biosciences is a cutting-edge biotech startup that operates in the pharmaceutical and medical device industries. The company specializes in targeted genetic sequencing and comprehensive genetic data collection, which are advanced techniques used to analyze and understand the genetic makeup of individuals. This information is crucial for the development of personalized treatments and therapies, particularly for chronic diseases.
Tesis Biosciences' primary clients are pharmaceutical and medical device companies. These companies rely on Tesis for genetic testing services and access to their extensive genetic database. This collaboration helps to de-risk drug development processes and accelerates the time it takes to bring new products to market.
In addition, Tesis partners with hospitals to provide high-complexity testing expertise and technology. This partnership enhances the quality and efficiency of patient care, as well as the timeliness of information flow. Physicians and large medical groups also benefit from Tesis' state-of-the-art genetic, pathology, and infectious disease testing systems, which enable them to design personalized, preventative care plans for their patients.
The company's business model revolves around providing these specialized services and access to its genetic database. Revenue is generated through service fees charged to pharmaceutical companies, medical device manufacturers, hospitals, and medical groups.
In summary, Tesis Biosciences is a revolutionary biotech company that leverages targeted genetic sequencing and data collection to improve drug development, disease management, and patient care.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Phoenix, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 83.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Tech for Biotech and Pharma, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VC✓Equity / VC | Oct 2021 | $20M | $520M | Xcellerant 1 TLC | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Tesis Labs is 280 monthly website visits. Tesis Labs's team grew 54.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- XTXcellerant 1 TLC
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tesis Labs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tesis Labs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







